BALLYA provide Covid 19 Neutralizing Antibody ELISA Test
, called cPass Test Kit, already approved by FDA EUA.
Studies have shown that NAbs play an important role in the development of immunity to a disease and are important considerations in vaccine development efforts1 . There is still much to learn about the NAbs that result from SARS-CoV-2
infection. The cPassTM SARS CoV-2 Neutralization Antibody Test
is an extremely useful, first-of-its-kind research assay that facilitates the specific detection of NAbs in a sample.
The traditional ELISA test kit will bind all types of antibodies in specimen, but cPass will bind the target antibody, that’s big different and increase positive and negative accuracy ratio. Show as below figure.
Detection of SARS-CoV-2 neutralizing (virus blocking) antibodies in the serum from recovering COVID-19 patients
Detection of SARS-CoV-2 neutralizing (virus blocking) antibodies in the serum from vaccinated patients
1.VanBlargan LA, Goo L, Pierson TC. Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiol. Mol. Biol. Rev. (2016).
2. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat. Biotechnol. (2020).